InVivo Therapeutics (NSDQ:NVIV) announced last week that it priced a public offering of common stock shares and warrants totaling approximately $7 million. The offering is set to include more than 2.5 million shares of common stock or pre-funded warrants to purchase common stock, along with standard warrants to purchase up to more than 2.5 million shares […]
InVivo Therapeutics stock down after reverse stock split
InVivo Therapeutics’ (NSDQ:NVIV) recently announced 1-for-30 reverse stock split went into effect last night, and shares have taken a hit today as a result. NVIV was down -10.2% at $6.95 per share in midday trading today. Cambridge, Mass.–based spinal cord injury treatment developer initially announced the common stock split earlier this month, sharing that every 30 […]
InVivo prices $1m public stock offering
InVivo Therapeutics (NSDQ:NVIV) announced that it priced a public stock offering expected to produce gross proceeds of just under $1 million for the company. The Cambridge, Mass.-based company is offering 7 million shares of its common stock to the public at a price of 12¢ per share. InVivo expects the gross proceeds to reach $840,000, before […]
Pixarbio CEO Reynolds convicted in $13m investor fraud case
Pixarbio founder & CEO Frank Reynolds reportedly faces two decades behind bars after a jury yesterday convicted him of defrauding investors of nearly $13 million. Federal authorities arrested Reynolds, longtime friend and Pixarbio employee Jay Herod and PixarBio CIO Kenneth Stromsland in April 2018 on securities fraud charges, claiming they misled investors about the opioid substitute […]
InVivo Therapeutics launches new neuro-spinal scaffold study
InVivo Therapeutics (NSDQ:NVIV) said today that it launched a new trial of its neuro-spinal scaffold, dubbed the INSPIRE 2.0 study, and that it has enrolled the first two patients into the study. The Cambridge, Mass.-based company won FDA approval to launch the new pivotal study of the device last March, after ending the previous Inspire study of the […]
InVivo Therapeutics releases 12-month Inspire study results
InVivo Therapeutics (NSDQ:NVIV) yesterday presented twelve-month results from the single-arm INSPIRE study of its neuro-spinal scaffold. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Results from the trial were presented at the 2019 AANS Meeting in […]
JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019
JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
InVivo inks joint research deal with cell therapy dev Q Therapeutics
InVivo Therapeutics (NSDQ:NVIV) said today it inked a joint research agreement with clinical-stage central nervous system cell therapy developer Q Therapeutics. Through the deal, InVivo is looking to combine its neuro-spinal scaffold technology with Q Therapeutics’ adult neural progenitor cells, Cambridge, Mass.-based InVivo said. Both companies will share their technologies and explore the potential combination’s safety […]
InVivo touts 1-year Inspire study results
InVivo Therapeutics (NSDQ:NVIV) today released 12-month results from the closed Inspire study of its neuro-spinal scaffold, touting improvements in ASIA impairment scales. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. Of the 16 patients in […]
InVivo Therapeutics shares down as losses grow in Q2 earnings release
Shares in InVivo Therapeutics (NSDQ:NVIV) fell today after the medical device maker missed expectations on Wall Street with its second quarter results. The Cambridge, Mass-based company posted losses of $12.9 million, or $7.48 per share, up 104.1% as compared with the same period during the previous year. Losses per share were well behind the 41¢ expectations […]
InVivo closes $15m round
InVivo Therapeutics (NSDQ:NVIV) said today it closed a new public offering, bringing in approximately $15.2 million. In the round, the Cambridge, Mass.-based company floated 388,000 shares and another 388,000 warrants at a combined price of $2 per unit, plus 6.2 million pre-funded warrants and 6.2 million standard warrants at $1.99 apiece. The round also included an […]
- 1
- 2
- 3
- …
- 17
- Next Page »
